MedTrace Logo

Extension Study on Safety and Rebound Effect of SAT-001 for Myopia in Children

NCT06742268 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-01-09

No results posted yet for this study

Summary

The objective of this clinical trial is to collect data on the rebound effect and long-term safety of SAT-001, a Software as a Medical Device (SaMD) under development for the inhibition and treatment of myopia progression in pediatric patients.

Conditions

  • Myopia

Interventions

OTHER

Single vision spectacles

Other interventions for myopia treatment, except for glasses, will not be provided.

Sponsors & Collaborators

  • S-Alpha Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Paik, MD · Gachon University Gil Medical Center

  • Lee, MD · Seoul Asan Medical Center

  • Han, MD · Kangbuk Samsung Hospital

  • Kim, MD · HanGil Eye Hospital

  • Kim, MD · Chung-Ang University Gwang Myeong Hospital

  • Park, MD · Daegu Fatima Hospital

  • Rhiu, MD · Hallym University Dongtan Sacred Heart Hospital

Eligibility

Min Age
5 Years
Max Age
8 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-16
Primary Completion
2025-10-30
Completion
2026-07-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06742268 on ClinicalTrials.gov